Two very important studies are enrolling patients and scheduled to be completed within the next 6 months.
1) Fabry study. Huge potential value for a small biotech company like PLX. Patients are dissatisfied with the current treatment and are hoping for a new and better medication.
2) Oral Gaucher study. Groundbreaking way to deliver medication. If effective could result in many patients switching over and making access easier for currently untreated patients. Also potential for other proteins to be delivered orally which would be amazing.
Investors should be patient. Sanofi and Shire must be watching very closely.